Search results
Added:
2 months ago
Source:
Radcliffe CVRM
A new study has found that the novel oral GLP-1 receptor agonist, orforglipron, demonstrated superior glycaemic control compared to oral semaglutide in adults with type 2 diabetes (T2D). The findings come from the ACHIEVE-3 trial, a phase 3 study published in The Lancet.¹Mechanism of ActionOrforglipron is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist designed for once-daily oral…
View more
Added:
1 year ago